Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
18 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall." is generating significant coverage in the Business category, with 23 articles from 18 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, BioSpace, finance.yahoo.com and tradingview.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 55d ago.
Quick answers
Why is "Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall." trending?
Because 18 independent news sources published 23 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (26)
- Viking Therapeutics Stock Surges 36% Following Weight Loss Drug Study Results Yahoo Finance · 56d ago
- Why Viking Therapeutics Stock Skyrocketed on Tuesday Currently.com · 56d ago
- Viking shares surge on updated obesity drug data BioPharma Dive · 56d ago
- Lilly Rises Higher as Viking Preserves Up to 90% Monthly Yahoo Finance · 56d ago
- Viking achieves ‘maintenance trifecta’ as GLP-1/GIP dual agonist exceeds expectations BioSpace · 56d ago
- VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win finance.yahoo.com · 56d ago
- VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win tradingview.com · 56d ago
- Lilly Rises Higher as Viking Preserves Up to 90% Monthly GuruFocus · 56d ago
- Viking Therapeutics Soars 36% on Clinical Trial Results: “An Important Step” TIKR.com · 56d ago
- VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results Barchart.com · 56d ago
- Why is Viking Therapeutics stock surging today? Investing.com · 56d ago
- Viking Therapeutics Stock Surges 26% After Weight-Loss Drug Trial barrons.com · 56d ago
- Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results Yahoo Finance · 56d ago
- Viking Therapeutics Stock Surges 36%+ Intraday. It Could Challenge Lilly and Novo's Obesity Empire Moomoo · 56d ago
- Viking touts once-a-month maintenance data for its weight loss candidate Endpoints News · 56d ago
- Viking shares surge on updated obesity drug data Yahoo Finance · 56d ago
- This GLP-1 drug helped people maintain their weight loss in a clinical trial MarketWatch · 56d ago
- 🔎Under the Radar: Viking Stock Gains on Weight-Loss Study WSJ · 56d ago
- Viking Therapeutics Stock Surges 30% After Weight-Loss Drug Trial Barron's · 56d ago
- Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing Yahoo Finance · 56d ago
- Viking Therapeutics stock soars on obesity data (VKTX:NASDAQ) Seeking Alpha · 56d ago
- Viking Soars as Obesity Shot Helps Cut Weight in Small Study Bloomberg.com · 56d ago
- Viking Therapeutics: The Market Might Shrug Off The Maintenance Data (NASDAQ:VKTX) Seeking Alpha · 56d ago
- Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens PR Newswire · 56d ago
- VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance Yahoo Finance · 56d ago
- Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. Investor's Business Daily · 56d ago
Topics
Related trends
Hundreds of children in England prescribed weight-loss jabs, figures show
New figures reveal hundreds of children in England, including under-12s, have been prescribed weight-loss jabs.
Validation of clinical and preclinical obesity across global cohorts
A new diagnostic framework for obesity that adds waist measurements to BMI outperforms BMI alone in identifying health risks and distinguishing clinical from pre-clinical obesity, according to a study of 844,108 adults across four countries published in Nature.
6-minute daily habit could help Ozempic users preserve muscle, expert says
A 40-week study found that resistance training helped people taking tirzepatide lose 25% less lean tissue while improving strength by 10%.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Obesity drugs may help protect memory and cognitive abilities - News-Medical
A major review of nearly 200 preclinical studies and major clinical trials finds that GLP-1 obesity drugs may protect the brain, but randomized trials have not shown a clear cognitive benefit.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The US Food and Drug Administration and Health Canada have approved bepirovirsen, marketed as Hibsago, as the first functional cure for chronic hepatitis B.